Treatment with ontamalimab was associated with both clinical and symptomatic remission in patients with ulcerative colitis (UC), according to data presented at the 2019 AIBD Annual Meeting held in Orlando, Florida.
Inflammatory bowel disease (IBD) diagnosis appears to be associated with high levels of anxiety and depression in children, however, new study findings presented at the 2019 AIBD Annual Meeting suggest that many of these patients may not be receiving appropriate mental health services.
Treatment with adalimumab or infliximab in biologic-naive patients with Crohn disease or ulcerative colitis demonstrated similar outcomes on Patient-Reported Outcomes Measurement Information System measures and rates of corticosteroid-free remission.
“The data indicate that more conservative periodontal therapy might initially be considered for IBD patients with advanced periodontal disease for whom PPI are prescribed as a component of their IBD treatment,” the authors concluded.
Combination biologic therapy may be an effective treatment option for patients with inflammatory bowel disease (IBD) who are refractory or have a concomitant autoimmune disease that is inadequately controlled by biologic monotherapy.
Proactive monitoring of adalimumab trough concentrations in children was associated with higher corticosteroid-free sustained remission and biologic remission rates compared with reactive monitoring in pediatric patients with Crohn disease.
IBD clinical trials have become increasingly complex as more specific clinical endpoints have gathered support within the academic arena. There has also been an emphasis on long-term extension safety and efficacy data which can further complicate recruitment.
Prospective studies are needed to determine what changes are significantly associated with treatment, whether these changes are causes or effects of response, and whether the composition of the intestinal microbiome can be used to select treatments for patients with IBD.
This study evaluated previously unreported data from the NHANES 2009-2010 and NHANES 2 (1976-1980) questionnaires that were used to compare axial pain rates among patients with and without inflammatory bowel disease.